Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Genincode PLC

Healthcare GB GENI

1.15GBX
0.00(0%)

Last update at 2026-06-05T15:04:00Z

Day Range

1.051.20
LowHigh

52 Week Range

0.905.50
LowHigh

Fundamentals

  • Previous Close 1.15
  • Market Cap7.77M
  • Volume5630923
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.06900M
  • Revenue TTM2.91M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 1.54M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -5.08300M -7.02300M -5.74600M -4.13600M -1.05814M
Minority interest - - - - -
Net income -4.43400M -7.01600M -5.55900M -4.14200M -1.06664M
Selling general administrative 1.86M 7.75M 6.27M 2.01M 1.57M
Selling and marketing expenses 0.25M 0.07M 0.14M 0.13M -
Gross profit 1.43M 1.02M 0.63M 0.59M 0.52M
Reconciled depreciation 0.35M 0.35M 0.16M 0.04M 0.02M
Ebit -5.03500M -6.99900M -5.89900M -3.53400M -1.05000M
Ebitda -4.68800M -6.64800M -5.56900M -2.88700M -1.03536M
Depreciation and amortization 0.35M 0.35M 0.33M 0.65M 0.01M
Non operating income net other - - - - -
Operating income -5.13400M -7.15100M -5.89900M -3.53400M -1.05000M
Other operating expenses 7.83M 9.31M 7.33M 4.69M 2.01M
Interest expense 0.05M 0.05M 0.01M 1.21M 0.00000M
Tax provision -0.64900M -0.00700M -0.18700M 0.00600M 0.00850M
Interest income 0.10M 0.17M 0.16M 0.00800M 0.00007M
Net interest income 0.05M 0.13M 0.15M 0.01000M -0.00813M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.64900M -0.00700M -0.18700M 0.00600M 0.00850M
Total revenue 2.70M 2.16M 1.43M 1.15M 0.96M
Total operating expenses 6.56M 8.17M 6.53M 4.13M 1.57M
Cost of revenue 1.27M 1.14M 0.80M 0.56M 0.44M
Total other income expense net 0.05M 0.13M 0.15M -0.60200M -0.00813M
Discontinued operations - - - - -
Net income from continuing ops -4.43400M -7.01600M -5.55900M -4.14200M -1.06664M
Net income applicable to common shares - - - -4.14200M -1.16600M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.66M 4.19M 11.80M 15.21M 2.42M
Intangible assets 0.12M 0.14M 0.16M 0.19M 0.14M
Earning assets - - - - -
Other current assets 0.20M 0.07M - 0.40M 0.25M
Total liab 1.54M 2.90M 3.90M 1.49M 0.56M
Total stockholder equity 1.13M 1.29M 7.90M 13.72M 1.86M
Deferred long term liab - - - - -
Other current liab 0.43M 1.77M 0.69M 0.49M 0.37M
Common stock 1.77M 0.96M 0.96M 0.96M 0.11M
Capital stock 1.77M 0.96M 0.96M 0.96M 0.11M
Retained earnings -19.94500M -15.51100M -8.49500M -2.86400M -1.57317M
Other liab - - - 0.66M -
Good will 0.00000M 0.15M 0.15M - -
Other assets - 0.00000M - - -
Cash 1.11M 2.48M 9.73M 14.55M 2.00M
Cash and equivalents - - - - -
Total current liabilities 1.38M 2.50M 2.39M 0.83M 0.56M
Current deferred revenue - 0.18M - - -
Net debt -0.87600M -2.18500M -9.37800M -14.55400M -2.00307M
Short term debt 0.17M 0.16M 0.28M - -
Short long term debt - - - - 0.00000M
Short long term debt total 0.23M 0.30M 0.35M - -
Other stockholder equity 18.48M 15.55M 15.44M 15.62M 3.32M
Property plant equipment - - 1.00M 0.05M 0.01M
Total current assets 2.10M 3.19M 10.48M 14.97M 2.27M
Long term investments - - - - -
Net tangible assets - - - 13.53M 1.72M
Short term investments 0.06M 0.04M 0.02M 0.00400M -
Net receivables 0.61M 0.51M 0.32M 0.23M 0.24M
Long term debt - - - - -
Inventory 0.13M 0.08M 0.02M 0.01M 0.02M
Accounts payable 0.61M 1.19M 1.42M 0.34M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.82M 0.29M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M -0.00100M 0.19M 0.00181M
Deferred long term asset charges - - - - -
Non current assets total 0.56M 0.99M 1.31M 0.24M 0.15M
Capital lease obligations 0.23M 0.30M 0.35M - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.05M 0.14M -0.84900M -0.14500M -0.06827M
Change to liabilities - - 2.02M 0.92M -0.03500M
Total cashflows from investing activities 0.05M 0.14M - -0.14500M -0.06800M
Net borrowings - - - - -
Total cash from financing activities 3.65M -0.09400M -0.04700M 15.86M 3.03M
Change to operating activities - - - -0.00200M -0.00200M
Net income -5.08300M -7.01600M -5.74500M -4.13700M -1.05814M
Change in cash -1.37400M -7.24800M -4.82200M 12.55M 1.92M
Begin period cash flow 2.48M 9.73M 14.55M 2.00M 0.09M
End period cash flow 1.11M 2.48M 9.73M 14.55M 2.00M
Total cash from operating activities -5.17300M -7.50600M -3.76200M -3.02400M -1.03778M
Issuance of capital stock 3.74M 0.00000M 0.00000M 15.86M 3.42M
Depreciation 0.35M 0.35M 0.16M 0.04M 0.02M
Other cashflows from investing activities 0.10M 0.17M - - -
Dividends paid - - - - -
Change to inventory -0.04200M -0.06500M -0.00600M 0.00400M -0.01816M
Change to account receivables -0.23100M 0.38M - -0.15000M 0.04M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.09800M -0.09400M -0.84900M -0.14500M -0.39686M
Change to netincome - - -0.26300M 0.31M 0.12M
Capital expenditures 0.05M 0.04M 0.85M 0.14M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.36300M -0.75300M 1.90M 0.77M -0.01062M
Stock based compensation 0.40M 0.07M 0.10M 0.07M -
Other non cash items 0.53M -0.15900M -0.17900M 0.23M 0.00820M
Free cash flow -5.22200M -7.54400M -4.61100M -3.16900M -1.10605M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GENI
Genincode PLC		 - -% 1.15 - - 2.67 3.00 1.94 -3.1541
IDHC
Integrated Diagnostics Holdings PLC		 0.02 3.77% 0.55 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 0.45 5.36% 8.85 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -0.75 5.88% 12.00 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 -0.125 6.49% 1.80 - - 7.05 1.50 6.07 -1.6211

Reports Covered

Stock Research & News

View All

Profile

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

Genincode PLC

One St. Peters Square, Manchester, United Kingdom, M2 3DE

Key Executives

Name Title Year Born
Mr. Matthew Heaton Walls CEO & Director 1964
Mr. Jordi Puig Gilberte COO & Director NA
Mr. Paul Andrew Peter Foulger CFO & Director 1970
Mr. Matthew Heaton Walls Co-Founder, CEO & Director 1964
Mr. Jordi Puig Gilberte Co-Founder, COO & Director 1975
Mr. Paul Andrew Peter Foulger CFO, Company Secretary & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions